Business Context and Reporting Period
uniQure N.V. is a gene therapy company focused on developing single-dose treatments for rare and devastating diseases. This Form 10-K covers the fiscal year ended December 31, 2024. The company's lead product candidate, AMT-130 for Huntington's disease, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in June 2024. In December 2024, the company reached an agreement with the FDA on key elements of an accelerated approval pathway for AMT-130. The company also advanced three other clinical candidates: AMT-260 (refractory mesial temporal lobe epilepsy), AMT-191 (Fabry disease), and AMT-162 (SOD1-ALS), dosing the first patients in trials for all three during 2024.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenues | $27.1 million | $15.8 million |
| Net Loss | $(239.6) million | $(308.5) million |
| Research & Development Expenses | $(143.8) million | $(214.9) million |
| Selling, General & Administrative Expenses | $(52.7) million | $(74.6) million |
| Cash, Cash Equivalents & Investments (Dec 31, 2024) | $367.5 million | $617.9 million |
| Long-term Debt (Principal) | $50.0 million | $100.0 million |
| Accumulated Deficit | $(1,130.0) million | $(890.4) million |
Revenue Composition: Revenues primarily consist of license royalties and collaboration services from CSL Behring regarding HEMGENIX. Contract manufacturing revenues decreased as the company divested its commercial manufacturing activities in July 2024.
Material Changes vs. Prior Period
- Restructuring and Divestiture: In July 2024, the company completed the "Lexington Transaction," selling its commercial manufacturing facility and operations to Genezen Holdings Inc. This resulted in a $1.2 million gain on divestment. Concurrently, the company executed a global organizational restructuring, eliminating approximately 300 positions (65% of the workforce) to conserve capital.
- Debt Reduction: In connection with the Lexington Transaction, the company repaid $50.0 million of its Hercules Capital term loan, reducing the outstanding principal from $100.0 million to $50.0 million, due in January 2027.
- Expense Reduction: R&D expenses decreased by $71.1 million and SG&A expenses decreased by $21.9 million compared to 2023, driven by the restructuring, reduced headcount, and the transfer of manufacturing costs.
- Financing Activity: In January and February 2025 (subsequent to the reporting period), the company raised approximately $80.7 million in net proceeds through a follow-on public offering of ordinary shares.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management expects that existing cash, cash equivalents, and investment securities, combined with the proceeds from the January 2025 offering, will be sufficient to fund operations through the second half of 2027. The company plans to initiate regulatory interactions with the European Medicines Agency (EMA) for AMT-130 in the first half of 2025 and intends to engage with the FDA regarding a potential Biologics License Application (BLA) submission.
Key Risks:
- Clinical Development: Success is heavily dependent on AMT-130. Interim data showed statistically significant slowing of disease progression, but final regulatory approval is not guaranteed. The company relies on post-hoc analyses and external controls, which may not be accepted by regulators.
- Manufacturing Dependence: Following the Lexington Transaction, the company relies on Genezen for the commercial manufacture of HEMGENIX and development services for its pipeline. Risks include Genezen's ability to meet supply requirements and regulatory standards.
- Capital Requirements: The company has a history of net losses and expects to incur losses in the future. Additional funding may be required to advance other pipeline candidates or commercialize AMT-130, which may not be available on acceptable terms.
- Regulatory Uncertainty: Changes in FDA policies regarding accelerated approval pathways or the new U.S. administration could impact the approval timeline or requirements for AMT-130.
Investor Verification Checklist
- Verify the specific statistical analysis plan and CMC requirements agreed upon with the FDA for the AMT-130 BLA submission.
- Monitor the performance of Genezen Holdings Inc. in manufacturing HEMGENIX and supplying clinical materials for the pipeline.
- Track the cash burn rate and the timeline for the next potential financing event, given the runway extends only to mid-2027.
- Review upcoming clinical data readouts for AMT-130 (specifically 3-year follow-up data) and the initiation of the third cohort.
- Assess the impact of the 65% workforce reduction on the company's ability to execute its clinical and regulatory strategy.